pharma · Acute Myeloid Leukemias · Breast Cancer
Syndax Pharmaceuticals
Syndax Pharmaceuticals patent portfolio — 6 USPTO pharmaceutical patents (A61K/A61P) with grant dates, status, and loss-of-exclusivity filters.
Company details
- Status
- Public
- HQ
- 730 3rd Ave, Floor 9, New York, NY 10017, US
- Employees
- 325
- Programs
- 47
- Drugs
- 29
- Patents
- 6
Syndax Pharmaceuticals patents
6 pharmaceutical patents indexed for Syndax Pharmaceuticals. 0 expire within 24 months.
Syndax Pharmaceuticals has 6 pharmaceutical patents in our USPTO PatentsView index (A61K/A61P). 0 expire within 24 months — use filters for patent-cliff planning.
Patent portfolio
-
US 12168054
Method of treating cancer using a combination of entinostat and an anti-CSF-1R antibody
granted -
US 12000829
Selection of patients for combination therapy
granted -
US 11919901
Inhibitors of the menin-MLL interaction
granted -
US 11397184
Selection of patients for combination therapy
granted -
US 11324822
Combination of HDAC inhibitor and anti-PD-1 antibody for treatment of cancer
granted -
US 10226472
Methods for the treatment of breast cancer
granted
Frequently asked questions
How many patents does Syndax Pharmaceuticals have?
6 published patents match the current filter (all indexed). The full portfolio is indexed from USPTO PatentsView (A61K/A61P).
When do Syndax Pharmaceuticals patents expire?
0 patents in the full portfolio expire within 24 months. Use the expiring filters above or open individual patent pages for grant and expiration dates.